Treatment Options for Anxiety in Substance Use Disorders
For individuals with substance use disorders and comorbid anxiety, the recommended approach is combined cognitive behavioral therapy (CBT) plus pharmacotherapy, which demonstrates superior outcomes compared to usual care alone. 1
Non-Pharmacological Interventions (First-Line)
Evidence-Based Psychotherapies
Cognitive Behavioral Therapy (CBT) combined with pharmacotherapy is the gold standard, showing significant benefit over usual care plus medication alone 1. However, CBT does not outperform other evidence-based therapies when both are combined with pharmacotherapy, meaning you have flexibility in choosing among validated approaches 1.
Other effective non-pharmacological options include:
- Neuromodulation techniques - Ranked highest for both anxiety and quality of life outcomes 2, 3
- Mind-body therapies - Top-ranked for depression, with robust efficacy across multiple outcomes 2, 3
- Exercise therapy - Most effective for alleviating depression (SUCRA: 90.77%) 3
- Motivational Interviewing (MI) - Particularly useful when integrated with CBT, as it addresses the motivation barrier when patients use substances to cope with anxiety 4, 5
- Family therapy, contingency management, and intensive case management - All validated behavioral interventions 4
Critical caveat: Avoid generic "usual clinical management" or nonspecific counseling—these are inferior to structured, evidence-based therapies 1.
Pharmacological Interventions (Adjunctive)
For PTSD + Alcohol Use Disorder
The evidence is strongest for this specific combination:
- Desipramine over paroxetine for anxiety symptom reduction (weak recommendation) 6
- Naltrexone to reduce anxiety symptoms (weak recommendation) 6
- SSRIs (sertraline, paroxetine) can reduce alcohol use but evidence is limited (weak recommendation) 6
General Pharmacological Principles
SSRIs/SNRIs are NOT unreservedly recommended for anxiety in substance use disorders—use them cautiously and only when clearly indicated 7. The evidence base is surprisingly limited, with trials only available for PTSD and social anxiety, and only in the context of alcohol use disorder 6.
Avoid or severely restrict:
- Benzodiazepines - Reserved EXCLUSIVELY for acute crisis management, never for ongoing anxiety treatment in this population 7
- Gabapentinoids - Require extremely careful risk-benefit analysis due to abuse and dependence potential in substance use populations 7
Medications Lacking Evidence
No controlled trials exist for anxiety treatment in patients using cocaine, cannabis, or nicotine despite these being common substances 6. This represents a major gap in the evidence base.
Practical Treatment Algorithm
Initiate combined treatment immediately - Don't treat anxiety or substance use in isolation; integrated treatment targeting both conditions simultaneously is essential 7, 8
Select primary psychotherapy: Choose CBT, mind-body therapy, neuromodulation, or exercise therapy based on:
Add MI components if patient shows low motivation or uses substances specifically to cope with anxiety 5
Consider pharmacotherapy adjunctively:
Intervention duration matters: Subgroup analyses suggest effects vary by intervention length—longer interventions may be needed in certain populations 2
Important Clinical Pitfalls
- Don't delay treatment waiting to determine which disorder is "primary"—rapid diagnosis and simultaneous treatment of both conditions is critical for success 7
- Don't use pharmacotherapy alone—the evidence clearly shows combined behavioral + pharmacological treatment is superior 1
- Don't assume all evidence-based therapies are equal for all substances—disease-specific efficacy profiles exist (e.g., CBT for OUD-related anxiety) 3
- Don't rely on treatment-as-usual or nonspecific counseling—these are demonstrably inferior 1
The evidence base remains limited, particularly for substances other than alcohol and for anxiety disorders beyond PTSD and social anxiety 6. In these evidence gaps, prioritize structured behavioral interventions over pharmacological approaches given the safety concerns and abuse potential in this vulnerable population.